# 510(k) Summary K05 067 8

#### SUBMITTED FOR:

Company Name:

Proxy Biomedical, Ltd.

Address:

Unit 6D, Mervue Business Park

Galway, IRELAND

Contact Person: Peter Mulrooney, Quality Assurance Manager,

Tel: +353 (0)91 709161

Fax: +353 (0)91 709162

Submitted by:

Elaine Duncan, M.S.M.E., RAC

President, Paladin Medical, Inc.

PO Box 560

Stillwater, MN 55082

715-549-6035 715-549-5380

CONTACT PERSON: DATE PREPARED: Elaine Duncan

March 14, 2005

TRADE NAME:

MOTIFMESH<sup>TM</sup> Soft Tissue Patch

**COMMON NAME:** 

Surgical Mesh

SUBSTANTIALLY EQUIVALENT TO: MOTIFMESH<sup>TM</sup> Soft Tissue Patch is substantially equivalent to the Bard PTFE Mesh. (Davol Inc.), Mersilene Mesh (Ethicon) and the Bard Mesh (Davol Inc.), a polypropylene mesh.

### **DESCRIPTION of the DEVICE:**

MOTIFMESH<sup>TM</sup> Soft Tissue Patch is a nonabsorbable, inert, sterile, macro porous surgical soft tissue patch produced from polytetrafluoroethylene. The MotifMesh <sup>TM</sup> Soft Tissue Patch is designed to facilitate the reinforcement and repair of damaged or ruptured soft tissue structures. The implant has a structure characterized by closed cell openings in a high strength film. The construction allows the soft tissue patch to be stretched in both directions, to accommodate and reinforce tissue defects. The soft tissue patch measures 0.006"+/.001" in thickness and exhibits high burst strength and tensile strength. Use of MOTIFMESH<sup>TM</sup> Soft Tissue Patch allows a fibroblastic response through the interstices of the implant, forming a strong fibrous wall.

#### **INDICATIONS FOR USE:**

MOTIFMESH<sup>TM</sup> Soft Tissue Patch is intended to assist in the repair and/or reinforcement of hernia and other fascial defects requiring the additional support of a nonabsorbable implant during and after wound healing.

## **SUMMARY of TESTING:**

Bench test data reveal the applicant device has mechanical and material characterisation values, which are substantially equivalent to the predicate devices. The biocompatibility test results show that the material used in the design and manufacture of the device are non-toxic and non-sensitizing to biological tissues consistent with their intended use.





MAY 2 0 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Proxy Biomedical, Ltd. C/o Ms. Elaine Duncan, M.S.M.E., RAC President Paladin Medical, Inc. P.O. Box 560 Stillwater, Minnesota 55082

Re: K050678

Trade/Device Name: MOTIFMESH™ Soft Tissue Patch

Regulation Number: 21 CFR 878.3300

Regulation Name: Surgical mesh

Regulatory Class: II Product Code: FTL Dated: March 14, 2005 Received: March 16, 2005

Dear Ms. Duncan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Miriam C. Provost, Ph.D.

-Acting Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

# Indications for Use

1050679

510(k) Number (if known):	_ , ,
Device Name:	MOTIFMESH™ Soft Tissue Patch
Indications For Use:	
MOTIFMESH™ Soft Tissue Phernia and other fascial defect during and after wound healing.	atch is intended to assist in the repair and/or reinforcement of s requiring the additional support of a nonabsorbable implant
. •	
Prescription UseX(Part 21 CFR 801 Subpart D)	AND/OR Over-The-Counter Use (21 CFR 807 Subpart C)  TOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)	
Concurrence of CDRH, Office of Device Evaluation (ODE)	

Control Contro